HR Execs on the Move

Injury Care Associates

www.injurycareco.com

 
Injury Care Associates is a physician-led occupational health clinic that specializes in helping employees get back to work and back to life after an injury. They offer workers compensation and employee health services in the Denver metro area.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

TissueGene

TissueGene is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Centric Medical Communications

Centric Medical Communications, Inc. is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Lac St Anne County

Lac St Anne County is a Sangudo, AB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Genetics Squared

Genetics Squared is a prognostics company focused on developing gene-based molecular assays for the prediction of cancer recurrence and proprietary point-of-care equipment for the evaluation and management of cardiovascular disease.

Relmada

Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.